Hypera has told the Brazilian competition authority that the pandemic hasn't affected its plans to buy and invest in Boehringer Ingelheim's antispasmodics and analgesics brands, but "reinforced" the need to "urgently" close the transaction, which involves the acquisition of a medicine that relieves symptoms of Covid-19. Hypera is planning to buy Boehringer Ingelheim's